Takeda And Cell Genesys Ink $270 Million Development Deal for GVAX Immunotherapy
This article was originally published in PharmAsia News
Executive Summary
PERTH, Australia - Japan-based Takeda and San Francisco-based Cell Genesys formed a global development alliance for Cell Genesys's lead product GVAX immunotherapy for prostate cancer, currently in Phase III trials
You may also be interested in...
Cancer Immunotherapy Sees Setback With Failure Of Takeda/Cell Genesys’ GVAX
Cell therapies have shown promise in treating cancer, but turning their possibility into reality so far has eluded the industry. Therefore, news Oct. 16 that one of the latest-stage therapies in development, Takeda/Cell Genesys' GVAX, failed in a second Phase III clinical trial represents, in some ways, a disappointment for the entire space
Cancer Immunotherapy Sees Setback With Failure Of Takeda/Cell Genesys’ GVAX
Cell therapies have shown promise in treating cancer, but turning their possibility into reality so far has eluded the industry. Therefore, news Oct. 16 that one of the latest-stage therapies in development, Takeda/Cell Genesys' GVAX, failed in a second Phase III clinical trial represents, in some ways, a disappointment for the entire space
Join The Club: Alnylam Signs On Takeda In RNAi Platform Deal
Takeda is the latest big pharma paying its way into Alnylam's not-so-exclusive club, with the firm having agreed to pay Alnylam $150 million upfront in exchange for worldwide, non-exclusive access to its RNA interference therapeutics platform technology in two therapeutic areas: oncology and metabolic disease